Ekso Bionics (NASDAQ:EKSO) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Tuesday morning. The firm issued a hold rating on the stock.

A number of other research firms also recently weighed in on EKSO. Lake Street Capital started coverage on Ekso Bionics in a research note on Monday, June 24th. They issued a buy rating and a $2.50 price target on the stock. HC Wainwright raised their target price on Ekso Bionics from $9.25 to $10.00 and gave the stock a buy rating in a report on Tuesday, April 30th.

Ekso Bionics Stock Performance

Shares of NASDAQ:EKSO opened at $1.00 on Tuesday. The business has a fifty day moving average of $1.14 and a 200-day moving average of $1.46. The firm has a market cap of $18.17 million, a PE ratio of -1.03 and a beta of 1.51. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.11 and a current ratio of 2.42. Ekso Bionics has a twelve month low of $0.62 and a twelve month high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings results on Monday, July 29th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The company had revenue of $4.95 million during the quarter, compared to analyst estimates of $5.34 million. Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. During the same period in the prior year, the business earned ($0.31) EPS. On average, equities research analysts predict that Ekso Bionics will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Ekso Bionics stock. Kent Lake Capital LLC acquired a new stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 141,158 shares of the company’s stock, valued at approximately $353,000. Kent Lake Capital LLC owned 0.95% of Ekso Bionics as of its most recent filing with the SEC. 6.42% of the stock is owned by institutional investors.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.